iLink (Incentives for Linkage to ART) Study: A Mixed-methods Study to Improve Linkage to HIV Care (iLink)

October 14, 2016 updated by: Brendan Maughan-Brown, University of Cape Town
The iLink Study examines whether a Conditional Economic Incentive (CEI) may be an effective tool for improving linkage to HIV treatment and care following referral for antiretroviral therapy (ART) services from a mobile health clinic in Cape Town, South Africa. The study examines the feasibility and acceptability of using a R300 (approximately $25 as of April 2015) voucher - that is exchanged for cash upon initiation of ART within 3 months - to increase the uptake of ART among men and women living in low-income areas. This pilot study (n=64) includes a randomised control trial, follow-up telephone calls and medical record reviews, and in-depth interviews.

Study Overview

Status

Unknown

Conditions

Detailed Description

The initiation of combination antiretroviral therapy (ART) remains a serious challenge globally, and particularly in South Africa, the country with the largest population of people living with HIV worldwide (UNAIDS 2012). South Africa has the largest ART programme globally, yet only half of those needing ART in South Africa were receiving treatment in 2011 (Johnson 2012). Early initiation of ART improves treatment outcomes and reduces AIDS-related morbidity and mortality. Recent studies have demonstrated a secondary benefit of ART in preventing HIV transmission by reducing viral load and thus transmissibility (Cohen et al. 2011; Montaner et al. 2010; Tanser et al. 2013). Despite the personal and public health benefits of ART, South African studies have shown large loss to follow-up at each of the stages required for ART initiation: (1) initial CD4 count testing and returning for results; (2) attending ART readiness counselling; and (3) returning to initiate ART (April et al. 2009; Bassett et al. 2010; Kranzer et al. 2010; Larson et al. 2010; Losina et al. 2010).

Novel interventions are urgently needed to improve linkage to HIV treatment and care post-diagnosis, as increased ART coverage will reduce AIDS-related morbidity and mortality, and HIV incidence. Improving ART coverage is therefore a priority in many regions of the world, and particularly in sub-Saharan Africa, where AIDS remains a key development challenge. Interventions based on theories from the field of behavioural economics, a hybrid of principles from psychology and economics (Bickel et al. 1995), have great potential to help strengthen the contributions of psychology to improving ART outcomes. Conditional economic incentives (CEIs), a financial incentive given upon completion of an outcome that can be objectively measured (i.e. ART initiation), has the potential to leverage two theoretical principles from behavioural economics to improve ART initiation. First, instead of being completely rational and accurate, decision-making is viewed as inherently biased due to a multitude of social-cognitive and affective factors that play a role in cost-benefit analysis, such as emotions, personal beliefs, and contextual factors (Fiske & Taylor 2008). In other words, people's preferred outcomes are largely determined by salient contextual needs (Operario et al. 2013). Second, people have a tendency to give greater value to rewards in the present or near future than those in the more distant future (a phenomenon economists term temporal discounting) and therefore decision-making favours immediate rewards and heavily discounts future outcomes. This poses a challenge for ART initiation as the future benefits of ART may be valued less than an individual's more immediate needs, especially for individuals who currently perceive themselves to be relatively healthy.

A CEI may help overcome this challenge for ART initiation by increasing its immediate benefits. A CEI may therefore help 'nudge' individuals to initiate ART by altering the cost-benefit ratio so that the benefits of ART (i.e. the immediate financial reward and the future health reward) outweigh the immediate costs of ART initiation, such as transport, time off work, long waiting lines and the fear of stigma. The application of CEIs to address HIV prevention and treatment problems is still in its infancy, but they have been successfully employed to improve adherence to ART (Rosen et al. 2007; Sorensen et al. 2007; Javanbakht et al. 2010), increase HIV testing uptake and the collection of HIV tests results (Thornton 2008), and reduce risky sexual behaviours (Baird et al. 2012). This evidence indicates that small incentives-based interventions can 'nudge' individuals towards adopting healthier behaviours.

The proposed research will make a significant contribution to our knowledge about demand creation for HIV treatment and prevention services by examining whether CEIs may also be an effective tool for improving linkage to HIV treatment and care following referral for ART services. The proposed research will examine the feasibility and acceptability of using CEIs to increase the uptake of ART among men and women who are referred for ART services. Our long-term collaborative goal is to utilize the results from this pilot study to prepare a grant application for a fully-powered RCT examining whether CEIs can increase ART initiation.

Objectives To examine the acceptability and feasibility of an incentive intervention aimed at increasing uptake of ART among men and women who are referred for ART (CD4 < 500 or WHO stage 4) by a mobile health clinic.

Acceptability

  • Did participants find the randomization process fair and acceptable?
  • Was the intervention an incentive that motivated or encouraged uptake of ART?
  • Was the incentive amount and type acceptable?
  • Were individuals in the control arm discouraged from ART initiation because they felt that their linkage to care efforts were not rewarded?
  • Were there cases of patients who were unsatisfied or disappointed as a consequence of the study (eg. they did not receive the incentive, yet they thought they should)?

Feasibility

  • Is it possible to recruit men and women into the study on the day of being referred for ART?
  • Is it possible to track individuals and recruit individuals for in-depth interviews?
  • Is it possible to implement the study as planned:

    • Did the randomization process work?
    • Did participants understand the incentive system?
    • Did participants believe that they would actually receive the incentive?
    • Did the incentive delivery method work?
  • What is the potential for individuals to game the incentive system? Did any individuals find a method of receiving the money without starting ART?

Potential Efficacy

  • Is ART initiation more likely among men and women who are offered the incentive compared to men and women who are not offered the incentive?
  • Is early ART initiation more likely among men and women who are offered the incentive compared to men and women who are not offered the incentive?
  • Does retention in care after ART initiation differ among men and women who are offered the incentive compared to men and women not offered the incentive?
  • What is the potential for incentives to improve ART initiation given participants behavioural intentions regarding ART initiation and barriers to ART initiation?

Study Type

Interventional

Enrollment (Actual)

87

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Western Cape
      • Cape Town, Western Cape, South Africa, 7705
        • Tutu Tester Mobile Clinic, Desmond Tutu HIV Foundation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Referred for ART by the Tutu Tester Mobile Clinic (CD4 ≤ 500 or WHO stage 4)
  • Planning to live in the study area for the next 6 months
  • Willing and able to provide written informed consent for study participation
  • Willing to accept calls from the study staff

Exclusion Criteria:

  • Participated in the study previously
  • Previously been on ART
  • Intoxicated at the time of enrolment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
The control arm receives standard of care. Standard of care involves referral for ART services and follow-up calls (maximum of 6) to assess whether linkage to care has occurred.
Experimental: Incentive
The incentive arm receives standard of care plus a R300 voucher. The R300 voucher can be exchanged for cash if the participant starts ART at any clinic of their choice within three months from study enrollment.

Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:

  1. Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and
  2. send a text message to the study team to let us know they have started ART;
  3. Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation.
Other Names:
  • CEI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ART initiation
Time Frame: 3 months
Commencement of antiretroviral therapy for HIV
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to ART initiation
Time Frame: 1-52 weeks
Days between referral for ART and ART initiation
1-52 weeks
Linkage to Care: first visit to clinic
Time Frame: 3 months
Self-reported attendance at an HIV/ART clinic within 3 months of study enrollment
3 months
Time to linkage to care
Time Frame: 1-52 weeks
Days between referral for ART and attendance at an HIV/ART clinic
1-52 weeks
ART retention
Time Frame: 12 months
Indicator of whether the participant collected his/her ART 1 year after starting treatment
12 months
Feasibility - accrual percentage
Time Frame: 6 months
Number of people enrolled in study/number approached for enrollment
6 months
Feasibility - participant tracking
Time Frame: 3 and 6 months post enrolment
Number of participants contact at 3 and 6 months/number of participants enrolled
3 and 6 months post enrolment
Acceptability - adverse events
Time Frame: 6 months
Unexpected risks/harms of providing incentives as self-reported by participants
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Brendan Maughan-Brown, PhD, University of Cape Town

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2015

Primary Completion (Actual)

July 1, 2016

Study Completion (Anticipated)

November 1, 2016

Study Registration Dates

First Submitted

April 24, 2015

First Submitted That Met QC Criteria

May 6, 2015

First Posted (Estimate)

May 12, 2015

Study Record Updates

Last Update Posted (Estimate)

October 17, 2016

Last Update Submitted That Met QC Criteria

October 14, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • HRECREF:849/2014

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV

Clinical Trials on Conditional economic incentive

3
Subscribe